|
|
Volumn 2, Issue 2, 2005, Pages 173-178
|
|
Is oncology compatible with specialty pharmacy?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;
CANCER;
CANCER CENTER;
CANCER CHEMOTHERAPY;
CANCER PATIENT;
CLINICAL PRACTICE;
COST BENEFIT ANALYSIS;
DRUG COST;
DRUG MARKETING;
HEALTH CARE ACCESS;
HEALTH CARE COST;
HEALTH CARE DELIVERY;
HEALTH CARE MANAGEMENT;
HEALTH CARE ORGANIZATION;
HEALTH INSURANCE;
HEALTH PROGRAM;
HEALTH SERVICE;
HUMAN;
MALPRACTICE;
MANAGED CARE ORGANIZATION;
MEDICAID;
MEDICAL DECISION MAKING;
MEDICAL LIABILITY;
MEDICARE;
ONCOLOGY;
OUTPATIENT CARE;
PATIENT EDUCATION;
PHARMACY;
PRIVATE HOSPITAL;
REVIEW;
|
|
EID: 15444375966
PISSN: 15485315
EISSN: None
Source Type: Journal
DOI: 10.1016/s1548-5315(11)70874-9 Document Type: Review |
|
Times cited : (5)
|
|
References (0)
|
